If drug research teams want to accelerate their R&D efforts they need to start demonstrating value in their content. Here’s how…
If you’ve been subscribing to an ad hoc content purchasing process, consider the benefits of creating a content portfolio to better understand the content investment.
With the help of big data, biomedical research can now access span swaths of medical records and test results to make smarter, swifter decisions.
It’s not until information managers draw attention to the importance of third party content and its value that they can start to validate its costs.
Every step towards creating a medical environment with access to anonymized open data is a step in the right direction.
Can I use content if I’m not profiting from it? How do Creative Commons and Digital Millennium Copyright Act (DMCA) fit into this?
A case of plagiarism may not be infringement – and vice versa. Make sure you understand the differences.